Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Biochemical Pharmacology|February 13, 2019
A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGCChristin Elgert, Anne Rühle, Peter Sandner, et al.Journal of Pharmaceutical and Biomedical Analysis|February 8, 2020
Thermal shift assay: Strengths and weaknesses of the method to investigate the ligand-induced thermostabilization of soluble guanylyl cyclaseChristin Elgert, Anne Rühle, Peter Sandner, et al.European Journal of Pharmacology|March 27, 2025
Discovery of the first isoform-specific sGC activator: Selective activation of GC-1 by runcaciguatSvenja Stomberg, Anne Rühle, Theresa Wittrien, et al.European Journal of Pharmacology|May 25, 2020
Tyrosine 135 of the β1 subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugsAnne Rühle, Christin Elgert, Michael G Hahn, et al.Biochemical Pharmacology|January 6, 2025
Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activationTheresa Wittrien, Anne Rühle, Christin Elgert, et al.European Journal of Endocrinology|April 5, 2024
Heterozygous gain of function variant in GUCY1A2 may cause autonomous ovarian hyperfunctionTheresa Wittrien, Alban Ziegler, Anne Rühle, et al.Pageof 1